Gilead’s remdesivir shows some benefit in patients with moderate Covid-19, new data show

(By Matthew Herper for STAT)

Remdesivir, the drug developed as a treatment for Covid-19 by Gilead Sciences, helped patients with “moderate” disease recover more quickly when they received it for five days, but the benefit was not statistically significant when given for 10 days, the company said Monday.  Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.